Evidence map›Paper›PMID 38837993›Full record

ArticlePloS one2024

Plasma taurine level is linked to symptom burden and clinical outcomes in post-COVID condition.

Mobin Khoramjoo, Kaiming Wang, Karthik Srinivasan, Mahmoud Gheblawi, Rupasri Mandal, Simon Rousseau, David Wishart, Vinay Prasad, Lawrence Richer, Angela M Cheung and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07312409 (Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07312409 recruitingnot on this mapstarted 2026, after this paper: background citation

Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?

Typeobservational_patient_registrySponsorYork UniversityRan2026 to 2027Enrolled30ConditionsLong COVID SyndromeArmsTaurine supplementation
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Network-based integration of metabolomics data from large-scale repositories.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Utility of Protein Markers in COVID-19 Patients.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mobin KhoramjooDepartment of Physiology, University of Alberta, Edmonton, Alberta, Canada.
Kaiming WangMazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Karthik SrinivasanDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, Canada.
Mahmoud GheblawiDepartment of Physiology, University of Alberta, Edmonton, Alberta, Canada.
Rupasri MandalThe Metabolomics Innovation Center, University of Alberta, Edmonton, Alberta, Canada.
Simon RousseauDepartment of Medicine, McGill University & The Research Institute of the McGill University Health Centre, Montreal, Canada.
David WishartThe Metabolomics Innovation Center, University of Alberta, Edmonton, Alberta, Canada.
Vinay PrasadDepartment of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, Canada.
Lawrence RicherDepartment of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Angela M CheungDepartment of Medicine, University Health Network, Toronto, Ontario, Canada.
Gavin Y OuditMazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-9154-9028

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA subset of individuals (10-20%) experience post-COVID condition (PCC) subsequent to initial SARS-CoV-2 infection, which lacks effective treatment. PCC carries a substantial global burden associated with negative economic and health impacts. This study aims to evaluate the association between plasma taurine levels with self-reported symptoms and adverse clinical outcomes in patients with PCC. METHODS AND

findingsWe analyzed the plasma proteome and metabolome of 117 individuals during their acute COVID-19 hospitalization and at the convalescence phase six-month post infection. Findings were compared with 28 age and sex-matched healthy controls. Plasma taurine levels were negatively associated with PCC symptoms and correlated with markers of inflammation, tryptophan metabolism, and gut dysbiosis. Stratifying patients based on the trajectories of plasma taurine levels during six-month follow-up revealed a significant association with adverse clinical events. Increase in taurine levels during the transition to convalescence were associated with a reduction in adverse events independent of comorbidities and acute COVID-19 severity. In a multivariate analysis, increased plasma taurine level between acute and convalescence phase was associated with marked protection from adverse clinical events with a hazard ratio of 0.13 (95% CI: 0.05-0.35; p<0.001).

conclusionsTaurine emerges as a promising predictive biomarker and potential therapeutic target in PCC. Taurine supplementation has already demonstrated clinical benefits in various diseases and warrants exploration in large-scale clinical trials for alleviating PCC.

Indexed as

COVID-19SARS-CoV-2TaurineAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMetabolomeMiddle AgedPost-Acute COVID-19 SyndromeSymptom BurdenBiomarkersTaurine

Identifiers

PMID38837993
PMCPMC11152273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.